Company Overview
About Adaptyv Biosystems
Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development.
Business Model & Competitive Advantage
Adaptyv's automated cloud laboratory eliminates the experimental bottleneck in the AI protein design cycle: AI protein design tools (AlphaFold structure prediction, RFdiffusion backbone generation, ProteinMPNN sequence design) can now generate thousands of theoretically promising protein candidates for therapeutic targets — but each candidate must be physically synthesized and experimentally tested to determine whether it actually binds its target, is stable in physiological conditions, and can be manufactured at therapeutic doses. Traditional wet lab testing (manual protein expression, purification, and characterization) creates the experimental throughput bottleneck that limits AI-guided protein engineering to testing a small fraction of computationally generated candidates. Adaptyv's automated cloud lab (robotic protein expression systems, automated biophysical characterization instruments, cloud-accessible data pipelines) processes protein candidates from DNA sequence to experimental binding and stability results in days rather than weeks, enabling AI protein design teams to run the experimental feedback loops required to optimize protein designs toward therapeutic-quality performance.
Competitive Landscape 2025–2026
In 2025, Adaptyv Biosystems competes in the protein engineering services, automated biofoundry, and AI drug discovery tools market with Twist Bioscience (NASDAQ: TWST, synthetic DNA for protein expression), Recursion Pharmaceuticals (NASDAQ: RXRX, AI drug discovery with robotic lab infrastructure), and Ginkgo Bioworks (NYSE: DNA, synthetic biology platform with automated labs) for pharma and biotech AI protein engineering experimental capacity. The AI protein engineering market has been transformed by the AlphaFold2 breakthrough (2020) and the subsequent development of protein generation tools (RFdiffusion, ProteinMPNN) that enable de novo protein design — but the experimental validation bottleneck has remained the rate-limiting step for translating computational designs into therapeutic candidates. Adaptyv's 5x success rate improvement from 2.5% to 13% demonstrates that the combination of AI-guided design and high-throughput experimental feedback creates measurably better protein candidates than computational design alone. The 2025 strategy focuses on growing the pharma partnerships for antibody and enzyme engineering programs, building the data flywheel from tested protein sequences to improve the AI design models, and expanding to protein-protein interaction engineering for the biologics immunotherapy market.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Adaptyv Biosystems is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Adaptyv Biosystems with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Adaptyv Biosystems? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Adaptyv Biosystems Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Adaptyv Biosystems vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →